Affinity and Specificity Maturation by CDR Walking

Kristiina Takkinen, Ari Hemminki, Hans Söderlund

Research output: Chapter in Book/Report/Conference proceedingChapter or book articleScientificpeer-review

Abstract

Random mutagenesis and phage display selection provide excellent tools for rapid engineering of the binding properties of antibodies for different applications. One strategy to optimise the antibody combining site is to mutate the CDRs in a stepwise manner. The CDRs are mutated and selected sequentially, after every round the best mutant is used as the template for the subsequent round of mutagenesis and selection. Yang et al. (1995) developed a high affinity anti-HIV gp 120 Fab by the CDR walking strategy in four steps. They were able to further increase the affinity (altogether 420-fold, Kd=1.5xlO_11M) by combining independently selected mutations, however, in this case only one of the six combinations constructed resulted in higher affinity demonstrating the unpredictable behaviour of parallel CDR optimisation. By stepwise optimisations of the light and heavy CDR3 regions and by using low, decreasing amount of biotinylated antigen in the selection steps Schier et al (1996) isolated an anti-c-erbB-2 scFv with picomolar affinity (Kd=1.3×lO_11M). The CDR walking and parallel optimisation strategies have also been used to improve the affinity and specificity of a monoclonal anti-testosterone antibody in the development of a clinically useful recombinant antibody (Hemminki et al, 1998a, b).
Original languageEnglish
Title of host publicationAntibody Engineering. Kontermann, R. & Dubel, S. (Eds)
EditorsRoland Kontermann, Stefan Dübel
Place of PublicationBerlin - Heidelberg - New York
PublisherSpringer
Chapter38
Pages540-545
ISBN (Electronic)978-3-662-04605-0
ISBN (Print)978-3-540-41354-7
DOIs
Publication statusPublished - 2001
MoE publication typeA3 Part of a book or another research book

Publication series

SeriesSpringer Lab Manuals

Fingerprint

Mutagenesis
Antibodies
Bacteriophages
Testosterone
Display devices
Binding Sites
Antigens

Cite this

Takkinen, K., Hemminki, A., & Söderlund, H. (2001). Affinity and Specificity Maturation by CDR Walking. In R. Kontermann, & S. Dübel (Eds.), Antibody Engineering. Kontermann, R. & Dubel, S. (Eds) (pp. 540-545). Berlin - Heidelberg - New York: Springer. Springer Lab Manuals https://doi.org/10.1007/978-3-662-04605-0_38
Takkinen, Kristiina ; Hemminki, Ari ; Söderlund, Hans. / Affinity and Specificity Maturation by CDR Walking. Antibody Engineering. Kontermann, R. & Dubel, S. (Eds). editor / Roland Kontermann ; Stefan Dübel. Berlin - Heidelberg - New York : Springer, 2001. pp. 540-545 (Springer Lab Manuals).
@inbook{3e0f790a9b2148338a46e75670f5d7fd,
title = "Affinity and Specificity Maturation by CDR Walking",
abstract = "Random mutagenesis and phage display selection provide excellent tools for rapid engineering of the binding properties of antibodies for different applications. One strategy to optimise the antibody combining site is to mutate the CDRs in a stepwise manner. The CDRs are mutated and selected sequentially, after every round the best mutant is used as the template for the subsequent round of mutagenesis and selection. Yang et al. (1995) developed a high affinity anti-HIV gp 120 Fab by the CDR walking strategy in four steps. They were able to further increase the affinity (altogether 420-fold, Kd=1.5xlO_11M) by combining independently selected mutations, however, in this case only one of the six combinations constructed resulted in higher affinity demonstrating the unpredictable behaviour of parallel CDR optimisation. By stepwise optimisations of the light and heavy CDR3 regions and by using low, decreasing amount of biotinylated antigen in the selection steps Schier et al (1996) isolated an anti-c-erbB-2 scFv with picomolar affinity (Kd=1.3×lO_11M). The CDR walking and parallel optimisation strategies have also been used to improve the affinity and specificity of a monoclonal anti-testosterone antibody in the development of a clinically useful recombinant antibody (Hemminki et al, 1998a, b).",
author = "Kristiina Takkinen and Ari Hemminki and Hans S{\"o}derlund",
year = "2001",
doi = "10.1007/978-3-662-04605-0_38",
language = "English",
isbn = "978-3-540-41354-7",
series = "Springer Lab Manuals",
publisher = "Springer",
pages = "540--545",
editor = "Roland Kontermann and D{\"u}bel, {Stefan }",
booktitle = "Antibody Engineering. Kontermann, R. & Dubel, S. (Eds)",
address = "Germany",

}

Takkinen, K, Hemminki, A & Söderlund, H 2001, Affinity and Specificity Maturation by CDR Walking. in R Kontermann & S Dübel (eds), Antibody Engineering. Kontermann, R. & Dubel, S. (Eds). Springer, Berlin - Heidelberg - New York, Springer Lab Manuals, pp. 540-545. https://doi.org/10.1007/978-3-662-04605-0_38

Affinity and Specificity Maturation by CDR Walking. / Takkinen, Kristiina; Hemminki, Ari; Söderlund, Hans.

Antibody Engineering. Kontermann, R. & Dubel, S. (Eds). ed. / Roland Kontermann; Stefan Dübel. Berlin - Heidelberg - New York : Springer, 2001. p. 540-545 (Springer Lab Manuals).

Research output: Chapter in Book/Report/Conference proceedingChapter or book articleScientificpeer-review

TY - CHAP

T1 - Affinity and Specificity Maturation by CDR Walking

AU - Takkinen, Kristiina

AU - Hemminki, Ari

AU - Söderlund, Hans

PY - 2001

Y1 - 2001

N2 - Random mutagenesis and phage display selection provide excellent tools for rapid engineering of the binding properties of antibodies for different applications. One strategy to optimise the antibody combining site is to mutate the CDRs in a stepwise manner. The CDRs are mutated and selected sequentially, after every round the best mutant is used as the template for the subsequent round of mutagenesis and selection. Yang et al. (1995) developed a high affinity anti-HIV gp 120 Fab by the CDR walking strategy in four steps. They were able to further increase the affinity (altogether 420-fold, Kd=1.5xlO_11M) by combining independently selected mutations, however, in this case only one of the six combinations constructed resulted in higher affinity demonstrating the unpredictable behaviour of parallel CDR optimisation. By stepwise optimisations of the light and heavy CDR3 regions and by using low, decreasing amount of biotinylated antigen in the selection steps Schier et al (1996) isolated an anti-c-erbB-2 scFv with picomolar affinity (Kd=1.3×lO_11M). The CDR walking and parallel optimisation strategies have also been used to improve the affinity and specificity of a monoclonal anti-testosterone antibody in the development of a clinically useful recombinant antibody (Hemminki et al, 1998a, b).

AB - Random mutagenesis and phage display selection provide excellent tools for rapid engineering of the binding properties of antibodies for different applications. One strategy to optimise the antibody combining site is to mutate the CDRs in a stepwise manner. The CDRs are mutated and selected sequentially, after every round the best mutant is used as the template for the subsequent round of mutagenesis and selection. Yang et al. (1995) developed a high affinity anti-HIV gp 120 Fab by the CDR walking strategy in four steps. They were able to further increase the affinity (altogether 420-fold, Kd=1.5xlO_11M) by combining independently selected mutations, however, in this case only one of the six combinations constructed resulted in higher affinity demonstrating the unpredictable behaviour of parallel CDR optimisation. By stepwise optimisations of the light and heavy CDR3 regions and by using low, decreasing amount of biotinylated antigen in the selection steps Schier et al (1996) isolated an anti-c-erbB-2 scFv with picomolar affinity (Kd=1.3×lO_11M). The CDR walking and parallel optimisation strategies have also been used to improve the affinity and specificity of a monoclonal anti-testosterone antibody in the development of a clinically useful recombinant antibody (Hemminki et al, 1998a, b).

U2 - 10.1007/978-3-662-04605-0_38

DO - 10.1007/978-3-662-04605-0_38

M3 - Chapter or book article

SN - 978-3-540-41354-7

T3 - Springer Lab Manuals

SP - 540

EP - 545

BT - Antibody Engineering. Kontermann, R. & Dubel, S. (Eds)

A2 - Kontermann, Roland

A2 - Dübel, Stefan

PB - Springer

CY - Berlin - Heidelberg - New York

ER -

Takkinen K, Hemminki A, Söderlund H. Affinity and Specificity Maturation by CDR Walking. In Kontermann R, Dübel S, editors, Antibody Engineering. Kontermann, R. & Dubel, S. (Eds). Berlin - Heidelberg - New York: Springer. 2001. p. 540-545. (Springer Lab Manuals). https://doi.org/10.1007/978-3-662-04605-0_38